How Nextech-led round will help Vividion to POC

$82M B round to advance small molecules from proteome-wide drug discovery platform

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest.

Now flush with over $165 million in cash, Vividion Therapeutics Inc. CEO Diego Miralles said the company will be able

Read the full 506 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE